付遠輝檢視原始碼討論檢視歷史
|
付遠輝，男，北京交通大學副教授。
人物簡歷
教育背景
2009年6月畢業於中國疾病預防控制中心病毒病預防控制所，獲得醫學博士學位。
工作經歷
2009年7月至今 北京交通大學理學院，一直從事病毒新型疫苗和病毒溶瘤方面的研究，作為主要成員先後參與和完成 「十二五」傳染病重大專項、「十二五」新藥創製重大專項、國家自然科學基金等項目多項，已在國內外高水平學術期刊發表論文30餘篇，申請中國發明專利6項，授權中國發明專利3項。
研究方向
生物化學與分子生物學
細胞生物學
科研項目
（1）聯合研發項目（KSL18015530），初免-加強型呼吸道合胞病毒載體疫苗，2018/05-2038/05，2000萬元，參加
（2）國家自然科學基金「面上」項目：人呼吸道合胞病毒複製缺陷型活疫苗與減毒活疫苗：免疫原性及安全性的比較研究，2018/01-2021/12，55萬元，參加
（3）校基本科研業務費，2014JBM123，呼吸道合胞病毒病毒樣顆粒黏膜免疫評價，2014/01－2014/12，8萬元，主持
（4）國家重大專項(民口)，2013ZX10004601，基於化學基因組學的病原診治生物標誌物高通量篩選平台，2013/01－2015/12，1578萬元，參加
（5）國家重大專項(民口)，2013ZX09103003-011，呼吸道合胞病毒減毒活疫苗研製，2013/01－2015/12，132.32萬元，參加
（6）校人才基金，2012RC050，呼吸道合胞病毒病毒樣顆粒製備及其免疫保護作用研究，2013/01－2014/12，2萬元，主持
（7）中國博士後科學基金，20100470196，靶向樹突狀細胞的呼吸道合胞病毒核酸疫苗的免疫效果研究，2010/09－2011/07，3萬元，主持
（8）校基本科研業務費，2009JBM104，以抗DEC205單鏈抗體靶向樹突狀細胞提高腺病毒載體疫苗免疫效果，2010/01－2011/12，5萬元，主持
（9）國家自然科學基金面上項目，30972604，提高以腺病毒載體為基礎的呼吸道合胞病毒疫苗安全性和有效性的方法研究，2010/01－2012/12，32.0萬元，參加
（10）北京市自然基金面上項目，7092053，呼吸道合胞病毒疫苗初免-加強免疫策略的研究，2009/01－2011/12/，12.0萬元，參加
學術成果
論文/期刊
Jie‑Mei Yu, Yuan‑Hui Fu, Xiang‑Lei Peng, Yan‑Peng Zheng & Jin‑Sheng He. Genetic diversity and molecular evolution of human respiratory syncytial virus A and B, Scientific Reports (2021) 11:12941,
Li-Nan Wang, Xiang-Lei Peng, Min Xu, Yuan-Bo Zheng, Yue-Ying Jiao, Jie-Mei Yu, Yuan-Hui Fu, Yan-Peng Zheng, Wu-Yang Zhu, Zhong-Jun Dong, Jin-Sheng He, Evaluation of the Safety and Immune Efficacy of Recombinant Human Respiratory Syncytial Virus Strain Long Live Attenuated Vaccine Candidates. Virologica Sinica, 2021, DOI: 10.1007/s12250-021-00345-3
Minghua Wang, Guoning Zhang, Jianyuan Zhao, Ningning Cheng, Yujia Wang, Yuanhui Fu, Yanpeng Zheng, Juxian Wang, Mei Zhu, Shan Cen, Jinsheng He, Yucheng Wang. Synthesis and antiviral activity of a series of novel quinolone derivatives as anti-RSV or anti-IAV agents. European Journal of Medicinal Chemistry, 214 (2021) 113208, DOI: 10.1016/j.ejmech.2021.113208
Jie-Mei Yu, Li-Shu Zhang, Yuan-Hui Fu, Feng-Min Ji, Han-Li Xu, Jia-Qiang Huang, Xiang-Lei Peng, Yan-Peng Zheng, Ying Zhang and Jin-Sheng He. Analysis of Continuous Mutation and Evolution on Circulating SARS-CoV-2. Evolutionary Bioinformatics, 2020, Volume 16: 1–6, DOI: 10.1177/1176934320954870
Guo-Ning Zhang, Qiang Li, Jianyuan Zhao, Xuandi Zhang, Zhuxin Xu, Yujia Wang, Yuanhui Fu, Qi Shan, Yanpeng Zheng, Juxian Wang, Mei Zhu, Ziqiang Li, Shan Cen, Jinsheng He, Yucheng Wang. Design and synthesis of 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides as novel dual inhibitors of respiratory syncytial virus and influenza virus A. European Journal of Medicinal Chemistry, 186 (2020) 111861
Yuan-Hui Fu; Zhu-Xin Xu; Nan Jiang; Yan-Peng Zheng; Marie-Anne Rameix-Welti; Yue-Ying Jiao; Xiang-Lei Peng; Ye Wang; Jean-Francois Eleouet; Shan Cen; Jinsheng He. High-throughput screening of active compounds against human respiratory syncytial virus. Virology, 535 (2019) 171–178
Yao Ma, Yue-Ying Jiao, Yun-Zhou Yu, Nan Jiang, Ying Hua, Xiu-Juan Zhang, Yuan-Hui Fu, Xiang-Lei Peng, Yan-Peng Zheng, Larry J. Anderson, and Jin-Sheng He. A Built-In CpG Adjuvant in RSV F Protein DNA Vaccine Drives a Th1 Polarized and Enhanced Protective Immune Response. Viruses 2018, 10, 38; doi:10.3390/v10010038.
Min Xu, Yue-Ying Jiao, Yuan-Hui Fu, Nan Jiang, Yuan-Bo Zheng, Yi-Fei Yan, Mei Zhang, Yan-Peng Zheng, Wu-Yang Zhu, Xiang-Lei Peng, Jin-Sheng He. Construction and characterization of a recombinant human respiratory syncytial virus encoding enhanced green fluorescence protein for antiviral drug screening assay. BioMed Research International, Volume 2018, Article ID 8431243, 8 pages，
Yue-Ying Jiao, Yuan-Hui Fu, Yi-Fei Yan, Ying Hua, Yao Ma, Xiu-Juan Zhang, Jing-Dong Song, Xiang-Lei Peng, Jiaqiang Huang, Tao Hong, Jin-Sheng He. A single intranasal administration of virus-like particle vaccine induces an efficient protection for mice against human respiratory syncytial virus. Antiviral Research, 2017，144： 57-69.
Ying Hua, Yue-Ying Jiao, Yao Ma, Xiang-Lei Peng, Yuan-Hui Fu, Xiu-Juan Zhang, Yuan-Bo Zheng, Yan-Peng Zheng, Tao Hong, Jin-Sheng He. Enhanced humoral and CD8 + T cell immunity in mice vaccinated by DNA vaccine against human respiratory syncytial virus through targeting the encoded F protein to dendritic cells. International Immunopharmacology, 2017, dx.doi.org/10.1016/j.intimp.2017，46：62-69
Yuan-Hui Fu, Ya-Ru Liu, Yan-Peng Zheng, Nan Jiang, Yue-Ying-Jiao, Yao Ma, Wei Li, Xiang-lei Peng, Jinsheng He. An RNA polymerase I-driven human respiratory syncytial virus minigenome as a tool for quantifying virus titers and screening antiviral drug. Chinese Chemical Letters, 2017, 28: 131-135
Ying Hua, Yue-Ying Jiao, Yao Ma, Xiang-Lei Peng, Yuan-Hui Fu, Yan-Peng Zheng, Tao Hong, Jin-Sheng He. DNA Vaccine Encoding Central Conserved Region of G Protein Induces Th1 Predominant Immune Response and Protection from RSV Infection in Mice. Immunology Letters, 2016，179：95-101
Yuan-Hui Fu, Yue-Ying Jiao, Jinsheng He, Gui-Yun Jiang, Wei Zhang Yao, Ma Ying Zhang, Chang-Xin Shi, Xiang-Lei Peng, Tao Hong, Yi-Fei Yan. Sublingual administration of a helper-dependent adenoviral vector expressing the codon-optimized soluble fusion glycoprotein of human respiratory syncytial virus elicits protective immunity in mice. Antiviral Research 105 (2014), 72-79, DOI: 10.1016/j.antiviral.2014.02.003
Yuan-hui Fu, Jin-sheng He, Wei Qiao, Yue-ying Jiao, Ying Hua, Ying Zhang, Xiang-Lei Peng, and Tao Hong. Intranasal immunization with a helper-dependent adenoviral vector expressing the codon-optimized fusion glycoprotein of human respiratory syncytial virus elicits protective immunity in BALB/c mice. Virol J, 2013, 10:183. DOI: 10.1186/1743-422X-10-183
Zheng YP, Tang Y, Fu YH, He JS,Wang XB, Hong T. Purification of human respiratory syncytial virus fusion glycoprotein. Protein Expr. Purif, 2012, 81(1): 115-118
Yuan-hui Fu, Rui-juan Lv, Li-ri Jin, Qiang Lu, Xiao-qiu Shao, Jin-sheng He, Li-wen Wu, Li-shu Zhang, Hong-gang Hu. Association of apolipoprotein E polymorphisms with temporal lobeepilepsy in a Chinese Han population. Epilepsy Res, 2010, 91(2-3): 253-259
Yuan-hui Fu, Jin-sheng He, Xiao-bo Wang, Xian-Xian Zheng, Qiang Wu, Can Xie, Wei Wei, Qian Tang, Jing-Dong Song, Jian-Guo Qu, Tao Hong. A prime–boost vaccination strategy using attenuated Salmonella typhimurium and a replication-deficient recombinant adenovirus vector elicits protectiveimmunity against human respiratory syncytial virus. Biochem Biophys Res Commun, 2010, 395(1): 87-92
Yuanhui Fu, Jinsheng He, Xianxian Zheng, Xiao-bo Wang, Can Xie, Chang-xin Shi, Mei Zhang, Qian Tang, Wei Wei, Jian-guo Qu and Tao Hong. Intranasal vaccination with a helper-dependent adenovirus vector enhances transgene-specific immune responses in BALB/c mice. Biochem Biophys Res Commun, 2010, 391(1): 857-861
Yuanhui Fu, Jinsheng He, Xianxian Zheng, Qiang Wu, Mei Zhang, Xiaobo Wang, Yan Wang, Can Xie, Qian Tang, Wei Wei, Min Wang, Jingdong Song, Jianguo Qu, Ying Zhang, Xin Wang, Tao Hong. Intranasal Immunization with a Replication-Deficient Adenoviral Vector Expressing the Fusion Glycoprotein of Respiratory Syncytial Virus Elicits Protective Immunity in BALB/c Mice. Biochem Biophys Res Commun, 2009, 381(4):528-532
專利
1、發明人：何金生；付遠輝；劉美琴；彭向雷；鄭妍鵬；黃蕾，中國發明專利：呼吸道合胞病毒全長融合前融合糖蛋白核苷酸序列、 重組腺病毒載體及其應用產品，專利號：ZL 202010863762.X，授權公告日：2022年09月30日。
2、發明人：何金生；付遠輝；彭向雷；鄭妍鵬，中國發明專利：一種共表達呼吸道合胞病毒融合前蛋白和黏附糖蛋白的複製缺陷型腺病毒載體疫苗，專利號：ZL 202010864874.7，授權公告日：2022年09月05日。
3、發明人：何金生；杜琳；付遠輝；朱衛華；彭向雷；高博；鄭妍鵬；劉美琴， 中國發明專利：一種針對呼吸道合胞病毒感染的組合疫苗，專利號：ZL 202010863764.9，授權公告日：2022年06月15日。
4、發明人：何金生；馬堯；付遠輝；彭向雷；鄭妍鵬，中國發明專利：一種呼吸道合胞病毒融合前F蛋白及其應用，專利號：ZL 201910337141.5，授權公告日：2021年09月10日。
5、發明人：何金生；王玉成；付遠輝；張國寧；徐竹欣；李強；鄭妍鵬；王菊仙；彭向雷；白曉光，中國發明專利：一類3-位官能團化的N(O,S)-雜茚類衍生物及其在抗呼吸道合胞病毒中的應用，專利號：ZL 201810109813.2，授權公告日：2020年09月24日。
6、發明人：何金生；彭向雷；許敏；付遠輝，中國發明專利：基於反向遺傳學構建的ＲＳＶ反基因組質粒及其應用，專利號：201710574632.2，授權公告日：2020年03月05日。
7、發明人：何金生；付遠輝；彭向雷；鄭研鵬；姜男；許敏，中國發明專利：一種呼吸道合胞病毒藥物的高通量篩選方法和應用，專利號：ZL201710244050.8，授權公告日：2019年07月04日。
8、發明人：何金生；付遠輝；焦月盈；洪濤，中國發明專利：一種呼吸道合胞病毒病毒樣顆粒及其製備方法和應用，專利號：ZL 201310667523.7，授權公告日：2016年08月24日。[1]